Cardax (CDXI) Stock Price

Cardax Price

OTC·CLOSED
0.00
​
Market closed

Revenue has compounded at 97.7% per year over the past 4 years to 539,000.00 USD. Cardax's net margin stands at -937.9%, up from -5,053.0% several years earlier.

Cardax stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cardax business model & stock analysis

Cardax Inc, a development stage biopharmaceutical company based in Honolulu, Hawaii, focuses on developing pharmaceuticals for chronic diseases driven by inflammation. The company has 10 full-time employees and went public via an IPO on January 30, 2012. Cardax is currently developing two pre-clinical pharmaceutical candidates: CDX-101 and CDX-301. CDX-101 is a proprietary astaxanthin prodrug designed to deliver astaxanthin to the bloodstream following oral administration. Astaxanthin is a naturally occurring molecule known for its anti-inflammatory properties, supporting cardiovascular health, metabolic health, liver health, joint health, and longevity. CDX-301 is a pharmaceutical candidate for macular degeneration, utilizing zeaxanthin, which accumulates in the human eye through a retinal receptor to protect against blue light, oxidative damage, and inflammation associated with macular degeneration. The company's headquarters are located in Honolulu, and it operates within the Health Care sector, specifically in the Pharmaceuticals industry. Cardax Inc's website is https://cardaxpharma.com/. The company is seeking to monetize its pre-clinical candidates, CDX-101 and CDX-301, as it advances its development pipeline. No additional details about the company's financials, specific acquisition history, or other product names are provided in the available information.

Frequently asked questions about Cardax

Converted at the current exchange rate, the Cardax share trades at 0.00 EUR (0.00 USD).

The revenue cannot currently be calculated for Cardax.

The profit cannot currently be calculated for Cardax.

The P/E ratio cannot be calculated for Cardax at the moment.

The P/S cannot be calculated for Cardax currently.

The Eulerpool Quality Score for Cardax is 2/10.

The ISIN of Cardax is US14141D2018. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Cardax is CDXI. The ticker symbol is used to trade Cardax shares on the stock exchange.

Fair ValueTerminal
0.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
53,900.00 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Jan 30, 2012
ISIN
US14141D2018
Cusip
14141D201
Market capitalization
80.25 USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
—
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
93.36 %
Last updated Oct 19, 2026, 7:41 AM

Cardax Peer Group

Cardax Ticker

OTC · CDXIOTC · CDXI

Cardax FIGI

CDXI:US · BBG0032KT1C9CDXI:PQ · BBG0032KT2X4CDXI:UV · BBG0032KT2Z2

All fundamentals and in-depth analysis of Cardax

Our stock analysis for Cardax stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cardax. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.